Montag A & Associates Inc. Reduces Holdings in AbbVie Inc. $ABBV

Montag A & Associates Inc. lessened its position in shares of AbbVie Inc. (NYSE:ABBV) by 3.7% during the 1st quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 72,244 shares of the company’s stock after selling 2,746 shares during the quarter. Montag A & Associates Inc.’s holdings in AbbVie were worth $15,712,000 at the end of the most recent reporting period.

A number of other large investors have also recently added to or reduced their stakes in the business. Chelsea Counsel Co. purchased a new stake in AbbVie in the third quarter valued at $26,000. Litman Gregory Wealth Management LLC acquired a new stake in shares of AbbVie during the 4th quarter worth about $28,000. Westend Capital Management LLC purchased a new stake in AbbVie in the 4th quarter valued at about $29,000. Imprint Wealth LLC lifted its position in AbbVie by 56.2% in the fourth quarter. Imprint Wealth LLC now owns 125 shares of the company’s stock valued at $29,000 after buying an additional 45 shares during the last quarter. Finally, Texas Capital Bancshares Inc TX acquired a new position in AbbVie in the third quarter valued at about $31,000. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: The European Commission approved TEPKINLY (epcoritamab) plus lenalidomide and rituximab for relapsed or refractory follicular lymphoma, making it the first and only bispecific-based therapy approved in Europe for this setting and expanding AbbVie’s oncology growth opportunity. Article Title
• Positive Sentiment: Cantor Fitzgerald raised its price target on AbbVie to $265 from $240 and reiterated an overweight rating, signaling continued analyst confidence in the stock’s outlook. Article Title
• Neutral Sentiment: Media coverage highlighted AbbVie as a high-yield dividend and “quality, low-stress” healthcare stock, which may support investor sentiment but does not change fundamentals. Article Title
• Negative Sentiment: AbbVie lowered its Q2 2026 EPS guidance to $3.57-$3.61 versus the consensus $3.77, suggesting earnings could come in below expectations. Article Title
• Negative Sentiment: The company also cut full-year 2026 EPS guidance to $13.91-$14.11, below the consensus estimate of $14.25, which may pressure the shares despite recent product wins. Article Title

AbbVie Stock Performance

Shares of ABBV stock opened at $254.71 on Wednesday. The stock has a market capitalization of $450.02 billion, a P/E ratio of 125.47, a price-to-earnings-growth ratio of 0.84 and a beta of 0.30. The company has a 50 day moving average price of $222.39 and a 200 day moving average price of $220.69. AbbVie Inc. has a fifty-two week low of $184.63 and a fifty-two week high of $261.64.

AbbVie (NYSE:ABBV) last released its earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.59 by $0.06. The company had revenue of $15 billion for the quarter, compared to analyst estimates of $14.72 billion. AbbVie had a net margin of 5.79% and a negative return on equity of 576.45%. The firm’s quarterly revenue was up 12.4% on a year-over-year basis. During the same period in the prior year, the business earned $2.46 EPS. On average, research analysts forecast that AbbVie Inc. will post 14.28 EPS for the current fiscal year.

AbbVie Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Friday, August 14th. Investors of record on Wednesday, July 15th will be paid a dividend of $1.73 per share. This represents a $6.92 annualized dividend and a yield of 2.7%. The ex-dividend date of this dividend is Wednesday, July 15th. AbbVie’s payout ratio is presently 340.89%.

Analyst Ratings Changes

A number of brokerages have weighed in on ABBV. DZ Bank upgraded shares of AbbVie from a “hold” rating to a “strong-buy” rating in a research report on Thursday, April 30th. Wells Fargo & Company set a $260.00 price objective on shares of AbbVie in a research report on Monday, June 22nd. Bank of America upgraded shares of AbbVie from a “neutral” rating to a “buy” rating and set a $234.00 target price for the company in a report on Thursday, April 30th. Cantor Fitzgerald boosted their target price on AbbVie from $240.00 to $265.00 and gave the company an “overweight” rating in a research report on Monday. Finally, Guggenheim restated a “buy” rating and set a $249.00 price target on shares of AbbVie in a research report on Friday, May 1st. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $256.67.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.